2 citations · 2 across the 3 of their papers we have counts for
3 papers
stat.ME2025
Using joint models in phase I dose-finding designs in oncology: considerations for frequentist approaches
Xijin Chen, Pavel Mozgunov, Richard D. Baird +1
Dose-finding trials for oncology studies are traditionally designed to assess safety in the early stages of drug development. With the rise of molecularly targeted therapies and im…
stat.ME2024
Next generation clinical trials: Seamless designs and master protocols
Abigail Burdon, Thomas Jaki, Xijin Chen +3
Background: Drug development is often inefficient, costly and lengthy, yet it is essential for evaluating the safety and efficacy of new interventions. Compared with other disease…
stat.ML2022★ 2 cited
Some performance considerations when using multi-armed bandit algorithms in the presence of missing data
Xijin Chen, Kim May Lee, Sofia S. Villar +1
When comparing the performance of multi-armed bandit algorithms, the potential impact of missing data is often overlooked. In practice, it also affects their implementation where t…